As our understanding of the different oncogenes that serve a role in the pathogenesis of lung cancer increases, so does the array of targets for the development of novel targeted therapies. In this exciting interview, James Spicer, PhD, FRCP, of Guy's and St Thomas' NHS Foundation Trust, London, UK, discusses emerging targets in development for non-small cell lung cancer (NSCLC). Prof. Spicer and covers AXL, including its potential for combating drug resistance, as well as previously poorly thought of targets, referencing HER2 and its targeting with the antibody-drug conjugate T-DM1. Prof. Spicer highlights the utility of the Stratified Medicine Programme and the National Lung Matrix Trial (NCT02664935) in identifying the activity of agents specific to these targets. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.